Geron CORP Form 4 insider transactions

EVP and Chief Commercial Officer of Geron Corporation, James Ziegler, purchased 100,000 shares of common stock at $1.60 per share on February 27, 2025.

Geron Corporation's CEO, John A. Scarlett, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC Form 4 filing.

Scott Alan Samuels, EVP and Chief Legal Officer of Geron Corporation, reports the acquisition of stock options and restricted stock units.

EVP and Chief Commercial Officer of Geron Corporation, James Ziegler, reports acquisition of stock options and restricted stock units.

Andrew J. Grethlein, EVP and Chief Operating Officer of Geron Corporation, was granted stock options and restricted stock units on February 18, 2025.

Michelle Robertson, EVP and Chief Financial Officer of Geron Corporation, reports the acquisition of stock options and restricted stock units.

Director Robert J. Spiegel acquired 2,206 shares of Geron Corp common stock on December 31, 2024, in lieu of a cash payment for his quarterly Board of Directors retainer fee.

EVP of Research and Development at Geron Corp, Joseph Eid, reports the acquisition of stock options.

Robert J. Spiegel, a director of Geron Corporation, acquired 1,767 shares of common stock in lieu of a cash payment for his quarterly Board of Directors retainer fee.

EVP, Chief Commercial Officer of Geron Corporation, James Ziegler, reports the acquisition of 1,600,000 stock options.

Andrew J. Grethlein, EVP and Chief Operating Officer of Geron Corporation, exercised stock options and sold shares on July 8, 2024.

Director Robert J. Spiegel reports acquisition of Geron Corp shares in lieu of cash payments for board retainer fees.

EVP and Chief Medical Officer of Geron Corporation, Faye Feller, exercised stock options and sold shares on June 10, 2024.

Anil Kapur, EVP, Corp Strategy & CCO of Geron Corporation, exercised stock options and sold the acquired shares on June 10, 2024.

Anil Kapur, EVP, Corp Strategy & CCO of Geron Corporation, acquired 250,000 shares of common stock via employee stock options after the FDA approved imetelstat.

Faye Feller, EVP and Chief Medical Officer of Geron Corporation, acquired stock options after the FDA approved imetelstat for lower risk MDS.

Geron Corporation's CEO, John A. Scarlett, acquired 1,000,000 shares of common stock through a vested employee stock option following FDA approval of imetelstat.

Scott Alan Samuels, EVP and Chief Legal Officer of Geron Corp, acquired 250,000 shares via a stock option that vested upon FDA approval of imetelstat.

Andrew J. Grethlein, EVP and Chief Operating Officer of Geron Corporation, acquired 452,804 shares via vested employee stock options following FDA approval for imetelstat.

Michelle Robertson, EVP and CFO of Geron Corp, reports the acquisition of 250,000 shares via stock option grant following FDA approval of imetelstat.

Geron Corporation's CEO, John A. Scarlett, executed a transaction involving the exercise and sale of 600,000 common stock shares under a pre-arranged 10b5-1 trading plan.

Director V. Bryan Lawlis exercised and sold Geron Corp stock options under a pre-arranged 10b5-1 trading plan.

Director John F. McDonald reports acquisition of 180,000 stock options in Geron Corporation.

Director Dawn Carter Bir reports the acquisition of stock options in Geron Corp.

Director Gaurav Aggarwal reports acquisition of 180,000 stock options in Geron Corp.

Director Robert J. Spiegel reports acquisition of 180,000 stock options in Geron Corporation.

Director Susan Molineaux reports acquisition of stock options in Geron Corporation.

Director V. Bryan Lawlis reports acquisition of 180,000 stock options in Geron Corp.

Director Elizabeth G. O'Farrell acquired stock options for 180,000 shares of Geron Corp on May 9, 2024.